News Briefing channel feed

Take­da-part­nered Evox signs up to $1.2B pact with Lil­ly; New liq­uid biop­sy com­pa­ny launch­es with $12M Se­ries A

5 years ago

In­s­med's an­ti-in­flam­ma­to­ry drug wins break­through sta­tus; Ky­owa Kirin backs new fund from 4BIO Cap­i­tal

5 years ago

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

6 years ago

Glax­o­SmithK­line cell ther­a­py lead leaves for part­ner; Fer­ring and Igenomix cre­ate Boston hub for ma­ter­nal health

6 years ago

For­bion leads $62.5M round for neu­ro start­up as ex-Te­va R&D chief takes con­trol; CSL Behring inks gene ther­a­py pact in im­munol­o­gy

6 years ago

No­var­tis chips in $10M for IPO-bound part­ner Pli­ant; Tenax shares soar on heart drug da­ta

6 years ago

Ab­b­Vie grabs SHP2 in­hibitors from Chi­na's Ja­co­bio; Chi-Med set on US fil­ing of su­r­u­fa­tinib

6 years ago

Min­er­va suf­fers an­oth­er CNS de­feat; Eli Lil­ly wins OK for tau-based Alzheimer's di­ag­nos­tic

6 years ago

Pro­tal­ix files BLA to com­pete with Sanofi Gen­zyme; Rally­bio col­lects an­oth­er Alex­ion alum

6 years ago

La Jol­la feels the burn of ri­val malar­ia ap­proval; With an­oth­er $10B, Bay­er could fi­nal­ly weed out its her­bi­cide prob­lem

6 years ago

Takeda's Alun­brig wins lung can­cer ap­proval; Atara of­fers an­oth­er pos­i­tive MS drug up­date

6 years ago

Re­struc­tured Melin­ta now wants to buy fel­low an­tibi­ot­ic mak­er Tetraphase; TA As­so­ciates mulls $500M deal for a stake in CD­MO

6 years ago

Eu­ro­pean reg­u­la­tors ac­cept Fi­bro­Gen's ane­mia drug for re­view; Pas­sage Bio's lead gene ther­a­py gets more love from the FDA

6 years ago

Si­lence Ther­a­peu­tics wants to list on Nas­daq while pur­su­ing new deals; Sur­face On­col­o­gy inks lat­est Keytru­da col­lab­o­ra­tion

6 years ago

Kin­tor Phar­ma­ceu­ti­cals com­pletes $240 mil­lion IPO; WuXi Bi­o­log­ics is open­ing a Boston plant

6 years ago

SEC backs Sino­vac's case against ac­tivist in­vestor who tried to take over; Blue­bird pen­cils in $400M raise

6 years ago

J&J jumps in­to gam­ma delta field with La­va col­lab­o­ra­tion; Myokar­dia guns for $605M raise

6 years ago

ADC up­sizes IPO of­fer­ing in search of a $175M-plus haul; No­vo presents en­cour­ag­ing GLP-1 da­ta from obe­si­ty study

6 years ago

Mer­ck pours $400M in­to flea drugs for Fi­do; Avro­bio shows dura­bil­i­ty; Rhythm gets pri­or­i­ty re­view

6 years ago

Chi­nese biotech aims $232M in IPO cash to push next-gen prostate can­cer drug; Im­munomedics rais­es near­ly a half-bil­lion off ap­proval

6 years ago

Fritz Ger­ber, who led Roche for 2 decades, dies; ADC Ther­a­peu­tics tries again for an IPO, sets terms

6 years ago

A new play­er en­ters the KRAS game with Fortress; Gilead picks up once-failed can­cer drug from Molo­gen's fire sale

6 years ago

An­oth­er sparse round of NASH da­ta; TG rais­es $60M af­ter PhI­II suc­cess

6 years ago

Ad­verum soars on ear­ly gene ther­a­py da­ta; BerGen­Bio rais­es €45.4M on the heels of Covid-19 move

6 years ago
First page Previous page 40414243444546 Next page Last page
A service from the Financial Times